Adlai Nortye：AN9025 仍需人體臨床驗證 (NASDAQ:ANL)
· seekingalpha.com
Adlai Nortye 的 AN9025 已開始給藥，但有效性數據預計要到 2027 年才會出爐。點擊此處閱讀 ANL 股票的最新分析。
Adlai Nortye Ltd. ( ANL ) is an oncology firm that currently develops three main candidates, which are AN9025, AN8025, and AN4035. All three assets now have Pha...